Skip to Content
Merck
CN

V-002

Verapamil hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C27H38N2O4·HCl
CAS Number:
Molecular Weight:
491.06
NACRES:
NA.24
UNSPSC Code:
41116107
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C27H38N2O4.ClH/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6;/h9-12,17-18,20H,8,13-16H2,1-7H3;1H

InChI key

DOQPXTMNIUCOSY-UHFFFAOYSA-N

SMILES string

Cl.COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

2-8°C

Quality Level

Gene Information

General description

Verapamil, a phenylalkylamine analog, is used to treat high blood pressure and angina. This analytical reference standard is applicable for use as starting material in calibrators or controls for verapamil testing methods by LC-MS/MS or GC-MS. A calcium channel blocker, verapamil is sold under trade names Calan® and Covera-HS®.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Calan is a registered trademark of G.D. Searle & Co.
Covera-HS is a registered trademark of G.D. Searle, LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Regulatory Information

危险化学品
This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Gargey B Yagnik et al.
Journal of mass spectrometry : JMS, 48(1), 100-104 (2013-01-11)
We have previously developed in-parallel data acquisition of orbitrap mass spectrometry (MS) and ion trap MS and/or MS/MS scans for matrix-assisted laser desorption/ionization MS imaging (MSI) to obtain rich chemical information in less data acquisition time. In the present study
Carsten Stengaard et al.
Ugeskrift for laeger, 175(1-2), 54-55 (2013-01-12)
Verapamil administered intravenously is recommended as a first-line therapy in patients with supraventricular tachycardia. However, these patients may suffer from tachycardia-induced heart failure and particular caution is needed before prescription of verapamil in these cases. We present a case of
Ping Liang et al.
Circulation, 127(16), 1677-1691 (2013-03-23)
Cardiotoxicity is a leading cause for drug attrition during pharmaceutical development and has resulted in numerous preventable patient deaths. Incidents of adverse cardiac drug reactions are more common in patients with preexisting heart disease than the general population. Here we
Rashmi Mehta et al.
International journal of chronic obstructive pulmonary disease, 8, 159-167 (2013-04-10)
The combination of umeclidinium (UMEC), a long-acting muscarinic receptor antagonist, and vilanterol (VI), a selective long-acting β₂ agonist, is in development for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the pharmacokinetics, safety and tolerability, and pharmacodynamics
Weidong Jia et al.
Cancer chemotherapy and pharmacology, 71(6), 1585-1590 (2013-04-17)
This study was designed to evaluate efficacy, toxicity, and adverse effects of combination of chemotherapy drugs and intraperitoneal perfusion of verapamil in the treatment of malignant ascites. Seventy-two patients with malignant ascites were divided into two study groups. Patients in

Protocols

LC/MS/MS Analysis of Interacting Cardiac Drugs Digoxin, Quinidine, Amiodarone and Verapamil on Titan™ C18

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service